Future studies will be designed to evaluate the effects of SBP-101 in combination with other polyamine metabolism modulators as well as with immune modulators. The results suggest that SBP-101 in common with doxorubicin may have a role in the clinical management of ovarian cancer, in particular, the platinum-resistant population where few options exist. These studies are the basis for moving into a clinical trial program in ovarian cancer with the goal of developing effective novel therapeutics in combinati ...